159 related articles for article (PubMed ID: 26788202)
1. Assessment of frequency and severity of hypomagnesemia in patients with metastatic colorectal cancer treated with cetuximab, with a review of the literature.
Streb J; Püsküllüoğlu M; Glanowska I; Ochenduszko S; Konopka K; Łupkowski R; Michalowska-Kaczmarczyk A; Bochenek-Cibor J; Majka M; Krzemieniecki K
Oncol Lett; 2015 Dec; 10(6):3749-3755. PubMed ID: 26788202
[TBL] [Abstract][Full Text] [Related]
2. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835
[TBL] [Abstract][Full Text] [Related]
3. Identifying optimal magnesium replenishment points based on risk of severe hypomagnesemia in colorectal cancer patients treated with cetuximab or panitumumab.
Kimura M; Usami E; Teramachi H; Yoshimura T
Cancer Chemother Pharmacol; 2020 Sep; 86(3):383-391. PubMed ID: 32789758
[TBL] [Abstract][Full Text] [Related]
4. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
[TBL] [Abstract][Full Text] [Related]
5. Temporary loss of consciousness during cetuximab treatment of a patient with metastatic colon cancer: a case report.
Fukui T; Suzuki K; Tamaki S; Abe I; Endo Y; Ishikawa H; Kakizawa N; Watanabe F; Saito M; Tsujinaka S; Futsuhara K; Miyakura Y; Noda H; Rikiyama T
Surg Case Rep; 2019 Oct; 5(1):145. PubMed ID: 31637554
[TBL] [Abstract][Full Text] [Related]
6. Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis.
Hsieh MC; Wu CF; Chen CW; Shi CS; Huang WS; Kuan FC
Sci Rep; 2018 Feb; 8(1):2047. PubMed ID: 29391418
[TBL] [Abstract][Full Text] [Related]
7. Risk Evaluation of Proton Pump Inhibitors for Panitumumab-Related Hypomagnesemia in Patients with Metastatic Colorectal Cancer.
Katsura H; Suga Y; Kubo A; Sugimura H; Kumatani K; Haruki K; Yonezawa M; Narita A; Ishijima R; Ikesue H; Toi H; Takata N
Biol Pharm Bull; 2024; 47(1):98-103. PubMed ID: 38171783
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions.
Saif MW; Kaley K; Chu E; Copur MS
Clin Colorectal Cancer; 2010 Dec; 9(5):315-8. PubMed ID: 21208847
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab-induced hypomagnesemia in patients with colorectal cancer.
Fakih MG; Wilding G; Lombardo J
Clin Colorectal Cancer; 2006 Jul; 6(2):152-6. PubMed ID: 16945172
[TBL] [Abstract][Full Text] [Related]
10. [Effect of magnesium supplementation on early-stage hypomagnesemia in patients treated with cetuximab].
Demizu M; Ueda H; Osawa M; Chihara S; Igarashi T; Yano K; Kimura F; Tanaka N; Hiratsuka M
Gan To Kagaku Ryoho; 2013 Jul; 40(7):897-900. PubMed ID: 23863731
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
12. Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies.
Petrelli F; Borgonovo K; Cabiddu M; Ghilardi M; Barni S
Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S9-19. PubMed ID: 21843103
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of Factors Influencing the Development of Hypomagnesemia in Patients Receiving Cetuximab Therapy for Head and Neck Cancer].
Inose R; Takahashi K; Nishikawa T; Nagayama K
Yakugaku Zasshi; 2015; 135(12):1403-7. PubMed ID: 26632157
[TBL] [Abstract][Full Text] [Related]
14. Magnesium monitoring practice in monoclonal anti-epidermal growth factor receptor antibodies therapy.
do Pazo-Oubiña F; Estefanell-Tejero A; Riu-Viladoms G; Anglada-Martínez H; Molas-Ferrer G; Creus-Baró N
J Clin Pharm Ther; 2013 Apr; 38(2):101-3. PubMed ID: 23278401
[TBL] [Abstract][Full Text] [Related]
15. Increase in cetuximab-induced skin rash and hypomagnesemia in patients receiving concomitant treatment with proton pump inhibitors (PPIs): a possible drug interaction?
Abu-Amna M; Bar-Sela G
Cancer Chemother Pharmacol; 2019 Mar; 83(3):545-550. PubMed ID: 30547192
[TBL] [Abstract][Full Text] [Related]
16. Assessment of skin-related toxicity in patients with metastatic colorectal cancer treated with cetuximab.
Pacek A; Kozioł M; Püsküllüoğlu M; Tomaszewski KA; Ochenduszko S; Zygulska AL; Krzemieniecki K
Acta Dermatovenerol Croat; 2014; 22(2):137-44. PubMed ID: 25102801
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab therapy and symptomatic hypomagnesemia.
Schrag D; Chung KY; Flombaum C; Saltz L
J Natl Cancer Inst; 2005 Aug; 97(16):1221-4. PubMed ID: 16106027
[TBL] [Abstract][Full Text] [Related]
18. Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports.
Langerak A; River G; Mitchell E; Cheema P; Shing M
Clin Colorectal Cancer; 2009 Jan; 8(1):49-54. PubMed ID: 19203897
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer.
Cao Y; Liao C; Tan A; Liu L; Gao F
Chemotherapy; 2010; 56(6):459-65. PubMed ID: 21088398
[TBL] [Abstract][Full Text] [Related]
20. A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer.
Yazdi MH; Faramarzi MA; Nikfar S; Abdollahi M
Avicenna J Med Biotechnol; 2015; 7(4):134-44. PubMed ID: 26605007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
